Jeffrey Holford

AbbVie Inc (NYSE: ABBV) shares are likely to rally with the expected near-term release of new data on two key drug candidates, an analyst said Monday. Jefferies' Jeffrey Holford maintained a Buy rating and $80 target on the company. AbbVie's recent selloff on fears of a price war...

Deutsche Bank and Stifel took differing positions on Eli Lilly and Co (NYSE: LLY) Thursday. Analyst Gregg Gilbert at Deutsche Bank downgraded the stock from Buy to Hold and maintained a $75 price target. Gilbert felt the stock had performed well in 2014, but little upside remained. “...

Jeffrey Holford of Jefferies speculates that consolidation "continues to look likely" for Zoetis Inc (NYSE: ZTS) in 2015. According to Holford, Zoetis' 2015 revenue guidance of $4.85 billion to $4.95 billion and earnings per share of $1.61 to $1.68 were both below expectations but...

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Zoetis (NYSE: ZTS), but lowered the price target from $40.00 to 39.00. In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income...

In a report published Friday, Jefferies analyst Jeffrey Holford downgraded the rating on Pfizer (NYSE: PFE) from Buy to Hold, and lowered the price target from $32.00 to $30.00. In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been...

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Merck (NYSE: MRK), but lowered the price target from $56.00 to $54.00. In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income...

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Johnson & Johnson (NYSE: JNJ), and raised the price target from $91.00 to $92.00. In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been...

In a report published Friday, Jefferies analyst Jeffrey Holford downgraded Bristol-Myers Squibb (NYSE: BMY) from Buy to Hold, and lowered the price target from $53.00 to $49.00. In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been...

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), but lowered the price target from $33.00 to $32.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in...

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Merck & Co. (NYSE: MRK), and raised the price target from $54.00 to $56.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection...

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Johnson & Johnson (NYSE: JNJ), but lowered the price target from $97.00 to $91.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth...

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), but lowered the price target from $53.50 to $53.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth...

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), but lowered the price target from $54.00 to $51.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential...

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), but lowered the price target from $46.00 to $44.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection...

In a report published Tuesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Zoetis (NYSE: ZTS), but lowered the price target from $41.00 to $40.00. In the report, Jefferies noted, “As the Pharmaceuticals Industry looks towards restructuring and separation of undervalued assets...